Publication | Closed Access

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

OncologyMedicineMelanomaImmune Checkpoint InhibitorDermatologyPhase 2Optimal CombinationPharmacologyCancer Treatment